Medvi vs Henry Meds GLP-1: Which Is Cheaper in 2026?
An independent, side-by-side comparison of MEDVi and Henry Meds for GLP-1 weight loss programs — pricing, medications, protocols, and patient experience.
Quick Verdict
Best Price
MEDVi
Starting at $50/mo vs $149/mo
Most Medications
MEDVi
2 medications vs 2
Best for Beginners
Henry Meds
Async Telehealth, fast onboarding
Head-to-Head Comparison
Pricing Breakdown
Side-by-side pricing for every medication.
| Medication | MEDVi | Henry Meds | Savings |
|---|---|---|---|
| Semaglutide | $50/monthly | $149/monthly | Save $99/mo with MEDVi |
| Tirzepatide | Not offered | $349/monthly | Only at Henry Meds |
Pros and Cons
MEDVi
- Video consultations with board-certified physicians
- Brand-name GLP-1 medications and orforglipron ($149/mo oral option) available
- Metabolic health coaching included at no extra cost
- Follow-up visits every 4-6 weeks
- Broad state coverage (47 states)
- Insurance accepted for brand-name medications
- Compounded GLP-1 options permanently unavailable
- Lab work not included in the program
- Founded in 2022 with a limited public track record compared to established competitors
- Physicians are not specifically obesity medicine specialists
- The "concierge" branding may set expectations higher than the actual level of personalization
- Not available in all 50 states
Henry Meds
- Among the lowest compounded GLP-1 pricing available
- Fast onboarding process (prescriptions within 24-48 hours)
- No consultation fee
- Free shipping included
- Async-only — no video consultations
- No lab testing included
- Relatively new company with limited track record
- Only compounded medications (no brand-name options)
How They Compare
Our editorial assessment across key dimensions.
In-Depth Comparison
By sarah-chen · Last updated April 15, 2026
Medvi vs Henry Meds GLP-1 (2026)
Medvi and Henry Meds compete directly in the lowest-cost tier of cash-pay GLP-1 telehealth. Both provide compounded semaglutide and tirzepatide at prices below most competitors; the differences are in pricing trajectory, clinical support, and which platform handles edge cases better.
Quick Comparison
| Medvi | Henry Meds | |
|---|---|---|
| Month 1–3 cost | ~$99–149/month | ~$149/month |
| Month 4+ cost | ~$99–149/month | ~$129/month (loyalty pricing) |
| Annual (semaglutide) | ~$1,188–1,788 | ~$1,614 ($149 × 3 + $129 × 9) |
| Tirzepatide access | Yes — compounded | Yes — compounded |
| Coaching | Minimal | Minimal |
| Lab testing | Not included | Not included |
| Insurance navigation | No | No |
| Provider access | Async primarily | Async primarily |
| Brand-name GLP-1 | No | No |
The Price Comparison
At face value, the pricing is very close:
| Scenario | Medvi (12 months) | Henry Meds (12 months) |
|---|---|---|
| Semaglutide low-end | ~$1,188 ($99 × 12) | $1,614 ($149 × 3 + $129 × 9) |
| Semaglutide mid-range | ~$1,428 ($119 × 12) | $1,614 |
| Tirzepatide | ~$1,788 ($149 × 12) | ~$1,788–2,100 |
At Medvi's lowest price tier (~$99/month), Medvi is ~$426/year cheaper than Henry Meds. If Medvi prices closer to $129/month (which some plans start at), the gap narrows to nearly nothing.
Important caveat: Henry Meds' $129/month loyalty pricing kicks in after month 3 — so for longer-term users, Henry Meds becomes more predictable and competitive. For the first 3 months, Henry Meds at $149/month is more expensive than Medvi at $99/month.
What Both Platforms Provide (and Don't)
What both provide:
- Licensed prescriber evaluation (questionnaire + review)
- Compounded semaglutide or tirzepatide prescription
- Mail-order delivery from compounding pharmacy
- Ongoing prescription refills
What neither provides:
- In-person care
- Lab review or ordering
- Insurance navigation or prior authorization
- Structured coaching or behavioral program
- Brand-name GLP-1 pathway
For patients who only need the prescription and medication delivered, both platforms are functionally equivalent.
When the Platform Differences Matter
| Scenario | Medvi Advantage | Henry Meds Advantage |
|---|---|---|
| First 3 months cost | ✓ Often cheaper | — |
| 12+ month sustained cost | Comparable | ✓ $129/month consistent |
| Track record/established | — | ✓ Larger patient base, longer history |
| Tirzepatide experience | Comparable | ✓ Slightly more established |
| Customer service responsiveness | Unclear | Moderate reviews |
Henry Meds has a longer track record (launched earlier) and has processed more patients through the compounded tirzepatide path — which provides somewhat more confidence in supply chain and provider familiarity.
The Bottom Line
For price-first patients who want the lowest possible cost for compounded GLP-1:
- Month 1–3: Medvi at ~$99/month wins if that tier is available to you
- Month 4+: Henry Meds at $129/month is comparable or slightly cheaper than Medvi's higher tiers
- Long-term: The ~$20–40/month difference is $240–480/year — meaningful over a multi-year medication commitment, but not transformative
If track record and supply chain stability matter: Henry Meds has processed more patients and has a longer operating history, which provides modest additional confidence.
If you want zero frills and lowest entry price: Medvi.
Related Resources
- Henry Meds GLP-1 Review — full program review
- Medvi Weight Loss Review — full program review
- Henry Meds vs Hims — Henry Meds vs mid-tier platform
- Medvi vs Ro GLP-1 — Medvi vs full-service option
- Best Cash-Pay GLP-1 Programs — full ranking of affordable GLP-1 programs
Related Guides
Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care
The best telehealth providers for tirzepatide in 2026, ranked by price, protocol, and care quality. From $278/month compounded to brand Zepbound via insurance. No provider paid for placement.
Read guide →Is Compounded Semaglutide Legal and Safe in 2026?
Is compounded semaglutide still legal? We break down the current FDA rules, 30 new warning letters, SAFE Drugs Act, Hims exiting compounded, and what this means for your prescription.
Read guide →Compounded Tirzepatide 2026: What's Happening and What Patients Should Do
Compounded tirzepatide is under active FDA enforcement as of March 2026 — supply is declining but not yet at zero. The 503B enforcement discretion ended over a year ago (March 2025); the FDA has now issued 50+ warning letters including a 30-letter batch in March 2026. Here's what patients need to know and what to do.
Read guide →